alan venook, md relays the optimal dose for regorafenib (stivarga) in the 2nd line treatment of mcrc
Published 8 years ago • 123 plays • Length 1:47
Download video MP4
Download video MP3
Similar videos
-
0:25
alan venook, md on integrating regorafenib and trifluridine into the 2nd line treatment of mcrc
-
1:13
alan venook, md, on the impact of dose escalation of regorafenib in mcrc patients
-
0:56
philip philip, md on stivarga (regorafenib) dosage in 2nd line treatment of mcrc
-
0:51
philip philip, md explains how to integrate regorafenib and trifluridine for 2nd line mcrc treatment
-
0:42
dr. bendell on the future of regorafenib for patients with crc
-
7:46
clinical use of regorafenib in mhcc
-
1:23
alan p. venook, md, on if the resorce trial will change the role of regorafenib
-
11:24
managing toxicities associated with regorafenib
-
26:20
colorectal cancer: the link between the immune microenvironment and outcomes
-
7:41
regorafenib in management of colorectal cancer – video abstract [id 88825]
-
5:19
stivarga moa. austin visuals
-
1:38
alan venook, md explains the outcome of phase 3 calgb/swog 80405 study
-
1:30
alan venook, md, discusses vemurafenib and the nccn guidelines for mcrc patients
-
2:12
alan venook, md, considers how i-o is evolving towards the first line treatment of colorectal cancer
-
5:53
redos trial: optimizing regorafenib dosing in metastatic colorectal cancer
-
5:25
second-line and salvage treatment of metastatic colorectal cancer
-
8:26
regorafenib in advanced colorectal cancer: dosing strategies
-
9:34
regorafenib in colorectal cancer
-
8:47
colorectal cancer: dosing strategies with regorafenib
-
1:45
jeffrey a. meyerhardt, md explains integration of stivarga and lonserf in later lines of treatment
-
8:14
optimizing treatment with regorafenib in metastic colorectal cancer
-
0:58
dr. kim reviews studies investigating regorafenib in mcrc
Clip.africa.com - Privacy-policy